Original Source(s)
Related Content
Endometrial cancer drug cuts progression or death risk 41%
FDA grants Priority Review following improved survival versus chemotherapy in phase 3 trial.
by Mouj Hijazi
October 27, 2026
-
3 min
H2-blocker tachyphylaxis may limit LPR therapy
Acid suppression wanes rapidly with repeated dosing, supporting intermittent use and phenotype-directed evaluation of persistent symptoms.
October 23, 2026
-
4 min
FDA rejects ivonescimab for lung cancer
Longer disease control without a statistically significant survival benefit did not support approval.
by Mouj Hijazi
November 16, 2026
-
2 min